Akut mieloid leukémia (AML): vizsgálatok itt: Észtország
7 trials · From ClinicalTrials.gov and EU CTIS (euclinicaltrials.eu), checked 2026. november 11.. Ask the study team whether a trial fits you.
- 3. fázisTaking peopleBleximenib in Combination With Standard Induction and Consolidation Therapy Followed by Maintenance for Treatment of Patients With Acute Myeloid Leukemia (AML)
- Where
- Tallinn, Tartu Linn
- Életkor
- 18 év and over
- People
- 875 worldwide
- Run by
- Stichting Hemato-Oncologie voor Volwassenen Nederland
See details and how to joinNCT07223814 · EU 2025-522767-15-00 - 3. fázisTaking peoplePhase III Study of Induction and Consolidation Chemotherapy With Venetoclax in Patients With Newly Diagnosed AML or MDS-EB-2
- Where
- Tallinn, Tartu Linn
- Életkor
- 18 év to 75 év
- People
- 650 worldwide
- Run by
- University of Ulm
See details and how to joinNCT04628026 · EU 2023-507518-28-00 - 3. fázisTaking peopleA study to investigate the effect of adding venetoclax to treatment with ivosidenib and azacitidine in patients with acute myeloid leukemia (AML) with a specific gene abnormality who have not previously been treated and who are not eligible for intensive chemotherapy.
- Where
- Tallinn, Tartu Linn
- Életkor
- 18 év and over
- People
- 180 worldwide
- Run by
- Hemato-Oncologie voor Volwassenen Nederland (Hovon) Stichting
See details and how to join2024-512753-24-00 · EU 2024-512753-24-00 - 3. fázisTaking peopleCHIP-AML22 Master protocol: Protocol for the treatment of children and adolescents with Acute Myeloid Leukemia (AML)
- Where
- Tallinn, Tartu Linn
- Életkor
- Up to 64 év
- People
- 675 worldwide
- Run by
- Prinses Maxima Centrum voor Kinderoncologie B.V.
See details and how to join2023-504999-25-00 · EU 2023-504999-25-00 - 3. fázisTaking peopleRevumenib in Combination With Azacitidine + Venetoclax in Patients NPM1-mutated or KMT2A-rearranged AML
- Where
- Tallinn, Tartu Linn
- Életkor
- 18 év and over
- People
- 448 worldwide
- Run by
- Stichting Hemato-Oncologie voor Volwassenen Nederland
See details and how to joinNCT06652438 · EU 2024-512733-32-00 - 3. fázisTaking peopleIvosidenib and Azacitidine With or Without Venetoclax in Adult Patients With Newly Diagnosed IDH1-Mutated AML or MDS/AML Considered Ineligible for Intensive Chemotherapy
- Where
- Tallinn, Tartu
- Életkor
- 18 év and over
- People
- 227 worldwide
- Run by
- Stichting Hemato-Oncologie voor Volwassenen Nederland
See details and how to joinNCT07075016 - 2. fázisTaking peopleCHIP-AML22/Quizartinib: Quizartinib + Chemotherapy in Newly Diagnosed Pediatric FLT3-ITD+ and NPM1wt AML Patients
- Where
- Tallinn, Tartu Linn
- Életkor
- 1 hónap to 18 év
- People
- 60 worldwide
- Run by
- Princess Maxima Center for Pediatric Oncology
See details and how to joinNCT06262438 · EU 2023-505000-27-01